Valuation: MiNK Therapeutics, Inc.

Market Cap 48.02M 42.68M 39.56M 36M 67.92M 4.56B 69.01M 476M 186M 2.38B 180M 176M 7.58B P/E 2026 *
-4.88x
P/E 2027 * -4.78x
Enterprise Value 48.02M 42.68M 39.56M 36M 67.92M 4.56B 69.01M 476M 186M 2.38B 180M 176M 7.58B EV / Sales 2026 *
14.1x
EV / Sales 2027 * 12x
Free-Float
40.63%
Yield 2026 *
-
Yield 2027 * -
1 day-5.33%
1 week-12.22%
Current month-25.02%
1 month-19.64%
3 months-11.73%
6 months-33.78%
Current year-15.61%
1 week 9.38
Extreme 9.38
11.24
1 month 9.38
Extreme 9.38
12.98
Current year 8.48
Extreme 8.4801
16.93
1 year 8.48
Extreme 8.4801
16.93
3 years 4.56
Extreme 4.5601
76
5 years 4.56
Extreme 4.5601
221.55
10 years 4.56
Extreme 4.5601
221.55
Manager TitleAgeSince
Chief Executive Officer 52 2021-01-31
Director of Finance/CFO 37 2026-03-12
Comptroller/Controller/Auditor 37 2026-03-12
Director TitleAgeSince
Director/Board Member 52 2021-01-31
Chairman 73 2017-06-30
Director/Board Member 62 2021-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Sell

Chief Executive Officer

-6,938 0.1360%
9/1/26 Free

Director

1,622 0.0318%
9/1/26 Free

Director

1,279 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
-5.33%-12.22%-32.79%-16.73% 48.02M
-6.60%-8.56%+49.38%+63.51% 65B
-4.09%-0.11%+2.22%+53.15% 51.19B
+0.03%+5.56%+9.10%+69.05% 51.2B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-2.76%-9.54%-16.58%-9.19% 22.03B
Average -2.20%-2.72%+34.09%+81.30% 37.2B
Weighted average by Cap. -2.30%-1.21%+42.14%+95.49%

Financials

2026 *2027 *
Net sales 3.4M 3.02M 2.8M 2.55M 4.81M 323M 4.89M 33.67M 13.2M 168M 12.76M 12.49M 537M 4M 3.56M 3.3M 3M 5.66M 380M 5.75M 39.61M 15.53M 198M 15.01M 14.69M 632M
Net income -9.6M -8.53M -7.91M -7.2M -13.58M -911M -13.8M -95.07M -37.28M -475M -36.03M -35.26M -1.52B -14.4M -12.8M -11.86M -10.79M -20.37M -1.37B -20.7M -143M -55.91M -713M -54.04M -52.89M -2.27B
Net Debt - -
Projected Income Statement - Annual - MiNK Therapeutics, Inc.
Logo MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Employees
15
Date Price Change Volume
26-10-16 US$9.410 -5.33% 13,626
26-10-15 US$9.940 -3.96% 10,095
26-10-14 US$10.35 +1.17% 6,017
26-10-13 US$10.23 -2.85% 7,172
26-10-12 US$10.53 -1.77% 18,781
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MiNK Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.410USD
Average target price
39.00USD
Spread / Average Target
+314.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MiNK Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. INKT Stock